Shares of Moderna Inc. mRNA,
fell 0.1% in premarket trading on Friday, after the company said the European Commission now intends to purchase another 80 million doses of its COVID-19 vaccine. The Commission has previously reached an agreement for 80 million doses. Moderna’s still-investigative vaccine requires two doses for each person, one month apart. It has not yet been approved or authorized in any country; however, an emergency use authorization from the Food and Drug Administration is always awaited. European Union health officials are expected to decide whether to grant a conditional marketing authorization for the vaccine on 6 January.
is increasing by 15.2%.